Since CD133 is thought to be one of CSC markers for CRC (23–25), we previously developed an anti-CD133 mAb (CMab-43, mouse IgG2a) (17) and investigated whether CD133 may represent a therapeutic target in colorectal adenocarcinoma using CMab-43 (26). This evidence concerns the gene PROM1 and colorectal adenocarcinoma.